• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Acotec Scientific touts 2-year data for DCB in femoropopliteal arteries

Acotec ScientificTwo-year data from the AcoArt I trial of Acotec Scientific‘s drug-coated balloon in patients with femoropopliteal arterial disease were touted yesterday at the VIVA conference by Dr. Wei Guo.

The study enrolled 200 Chinese patients with peripheral artery occlusive disease and randomized them to receive the Acotec’s Orchid paclitaxel-coated balloon or a standard balloon catheter.

The trial’s primary endpoint was angiographic late lumen loss at six months, as measured by a blinded core lab. Researchers also examined clinical endpoints after 12 and 24 months.

The patient population was 74% male and had an average age of 66 years old. The researchers added that 31% of participants were smokers and 55% were diabetic. They had an average lesion length of 150 millimeters, 25% in-stent restenosis, 55% occlusion or partial occlusion and 20% had provisional stenting.

Late lumen loss after 6 months was 0.05 (+/- 0.73) millimeters in the group that received the DCB and 1.15 (+/- 0.89) in the group that received the uncoated balloon.

Also, primary patency after 24 months was 64.6% for the DCB group and 31.4% for the uncoated balloon group, the researchers reported.

After two years, the rate of freedom from clinically driven target lesion revascularization was 86.5% for those treated with the DCB and 58.6% for those treated with the uncoated balloon.

The team also reported that there were no significant differences between groups in the rates of death and major amputation.

“This demonstrates strong durability through 2 years with superior performance in primary patency for the Orchid DCB versus PTA,” the presentation said. “AcoArt I demonstrates the safety and efficacy of the Orchid DCB in treating femoropopliteal artery disease and sustained durability of the DCB treatment effect with no late catch-up through 2 years.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS